

SEP 25 2007

Attorney Docket No. 57636-8013.US01

Remarks

Claims 27-32 are pending. Claim 1 is being amended. No claims are being cancelled or added. Thus, after entry of this Amendment, claims 27-32 are pending and under consideration.

I. The Amendments of the Claims

In this Amendment, claim 27 has been amended for technical clarity by reciting that the isolated polypeptide "induces an immune response to human prostatic acid phosphatase." Support for the amendment can be found throughout the specification, such as on page 2, lines 14-19 and lines 23-28. The amendment merely rephrases the term "immunologically crossreactive" as understood by those skilled in the art and does not affect the scope of the claim term. The amendment does not introduce any new matter. Entry is therefore respectfully requested.

II. Substance of Examiner Interview Under 37 C.F.R. § 1.133(b)

On September 25, 2007, the Examiner contacted the undersigned to suggest amendments in the claim language to advance the prosecution of this case. Various alternative forms were discussed.

III. Conclusion

Applicant respectfully requests expeditious consideration of the amendments, and if the claims are in form for allowance, an early notification of such is requested. If the Examiner believes that any remaining issues are better resolved by a telephone conference, the Examiner is cordially invited to contact the undersigned at 650-838-4365.


No fees are believed due in connection with this Amendment. However, the Director is authorized to charge any fees that may be required, or credit any

Attorney Docket No. 57636-8013.US01

overpayment, to Perkins Coie LLP Deposit Account No. 50-2207 (Order No. 57636-8013.US01).

Respectfully submitted,

Date: September 25, 2007

  
\_\_\_\_\_  
Euk Y. Oh  
Reg. No. 54,345

Perkins Coie LLP  
**Customer No. 22918**  
Tel: (650) 838-4300  
Fax: (650) 838-4350